Banking & Finance  April 13, 2022

Statera Biopharma faces delisting from Nasdaq, allegations of defaulting on loan

FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB) is in danger of being delisted from the Nasdaq exchange after a sustained dip in its stock price and allegations of defaulting on a loan that led to the resignation of two members of its board of directors, according to documents filed with the Securities and Exchange Commission.

Statera is a medical drug company whose leading candidates are designed to treat Crohn’s disease and pancreatic cancer. It first received a delisting notice from Nasdaq on March 23, when it was informed that it was in violation of the bid price rule — the…

Related Posts

Sign up for BizWest Daily Alerts